CML Horizons 2017 Registration Now Open - 26-28 May 2017
Register here - Preliminary Program - Conference fee - Scholarship Application
- Call for Abstracts - Call for Posters - Travel - Visas - Venue & Accommodation - Acknowledgements - Call for Nominations
Registration is now open - Join us for the 15th “CML Horizons: Learn. Share. Grow" Conference
DATE: 26TH TO 28TH MAY 2017
LOCATION: FRANKFURT, GERMANY
Equip yourself with knowledge on how to make a difference to the lives of patients, identify opportunities in patient support & advocacy, empower yourself & gain the courage to fight for the rights of CML patients, learn from the experts - both patient advocates and physicians.
This exciting one of its kind conference will enable you to be able to exchange ideas, interact & share best practice. You will also have the opportunity start networking across borders and build alliances and so much more for you to bring back to your own organization.
IMI Project "HARMONY - Big Data for Better Health Outcomes" launched, CML Advocates Network involved in coordinating patient community input
The Innovative Medicines Initiative (IMI) has approved HARMONY, a 5-year project that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies.
We are very excited that CML Advocates Network will be contributing to this unique project. Jan Geissler is the Work Package leader that will be coordinating HARMONY's Stakeholder Forum and patient input of the haematology patient community into this project. The project will kick-off on 16 January 2017 in Salamanca, Spain.
CML Horizons 2017 - Save the date: 26-28 May 2017
Join us for the 15th “CML Horizons: Learn. Share. Grow" Conference
DATE: 26TH TO 28TH MAY 2017
LOCATION: FRANKFURT, GERMANY
Equip yourself with knowledge on how to make a difference to the lives of patients, identify opportunities in patient support & advocacy, empower yourself & gain the courage to fight for the rights of CML patients, learn from the experts - both patient advocates and physicians.
This exciting one of its kind conference will enable you to be able to exchange ideas, interact & share best practice. You will also have the opportunity start networking across borders and build alliances and so much more for you to bring back to your own organization.
Registration process will start the 2nd week of January 2017 and will inform you as soon as the registration platform is online.
3 comments
ASH 2016 update on stopping CML treatment with TKIs in deep molecular response
Tyrosine kinase inhibitors (TKI) have dramatically improved survival of CML and made it a chronic disease. However, life-long therapy is still advised according to expert recommendations and the product labels of current TKI treatments. Depending on the choice of TKI, about 40-70% of CML patients reach a deep molecular response, meaning a BCR-ABL ratio of 0.01% (MR4) or below. Given it had been observed that some patients were able to stop treatment in deep remission without a recurrence of the disease, the effectiveness of stopping TKI treatment of CML patients at large having a sustained, deep molecular response is a key question that is being investigated in various studies, and is probably the most debated CML topic at this year’s ASH.
We are summarizing the most important presentations, discussions and posters on that important topic at the ASH congress this year.
Webinar: GENERIC TKIs IN CML
The Glivec patent expires in most countries latest on 21 Dec 2016.
The CML Advocates Network has been following the situation of TKI generics closely for 3 years, and has now provided a webinar which summarizes the current status.
This webinar answers some important questions, such as:
- What are generics, and do they differentiate from innovator products?
- Which generics of CML Tyrosine Kinase Inhibitors exist?
- What do we know about efficacy and safety?
- What information on CML generics is available to patients?
- What has the patient advocacy community done so far?
- What can patients and patient advocacy groups do about CML generics?
More can be found on our CML Advocates Network Knowledge Base on CML Generics at http://www.cmladvocates.net/generics.
If you want access to the slides, please contact Jan Geissler at .
Webstream via AuthorStream (allows to skip slides)
Welcome, CML Palestine (Palestine) - now 110 patient organisations from 83 countries in the CML Advocates Network
We are proud to welcome a new member organisation to the CML Advocates Network: CML Palestine based in Palestine. The CML Advocates Network now totals at 110 member organisations in 83 countries worldwide! See the list of CML groups in the Network on our world map.
